Loading…
Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA
Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs)...
Saved in:
| Published in: | Cancer investigation 2018-02, Vol.36 (2), p.118-128 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c366t-38f7c088b9300552fb7389a03e70d6b9477ad5b4c9264d5a23b09969c3a12d1a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c366t-38f7c088b9300552fb7389a03e70d6b9477ad5b4c9264d5a23b09969c3a12d1a3 |
| container_end_page | 128 |
| container_issue | 2 |
| container_start_page | 118 |
| container_title | Cancer investigation |
| container_volume | 36 |
| creator | Psimadas, Dimitrios Valotassiou, Varvara Alexiou, Sotiria Tsougos, Ioannis Georgoulias, Panagiotis |
| description | Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa). |
| doi_str_mv | 10.1080/07357907.2018.1430816 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_29393702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1993989820</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-38f7c088b9300552fb7389a03e70d6b9477ad5b4c9264d5a23b09969c3a12d1a3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EgvL4BFCWbFLGdhLbOyrES4BAUNbWJHZKkBMXOxXq35OohSWrWcy5czWHkFMKUwoSLkDwXCgQUwZUTmnGQdJih0xozlmaUcV2yWRk0hE6IIcxfsJAMpHvkwOmuOIC2IQ8vKJpvMPSOmuSdlbGBGPy5J2tVg5Dct_ioukWCXbmwodk_mEDLtfJbGG7PiZzDAvbj_uXt6fZMdmr0UV7sp1H5P3men51lz4-395fzR7TihdFn3JZiwqkLBUHyHNWl4JLhcCtAFOUKhMCTV5mlWJFZnJkvASlClVxpMxQ5EfkfHN3GfzXysZet02srHPYWb-KmqrhPakkgwHNN2gVfIzB1noZmhbDWlPQo0f961GPHvXW45A721asytaav9SvuAG43ABNV_vQ4rcPzuge186HOmBXNVHz_zt-AI4qf6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1993989820</pqid></control><display><type>article</type><title>Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Psimadas, Dimitrios ; Valotassiou, Varvara ; Alexiou, Sotiria ; Tsougos, Ioannis ; Georgoulias, Panagiotis</creator><creatorcontrib>Psimadas, Dimitrios ; Valotassiou, Varvara ; Alexiou, Sotiria ; Tsougos, Ioannis ; Georgoulias, Panagiotis</creatorcontrib><description>Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa).</description><identifier>ISSN: 0735-7907</identifier><identifier>EISSN: 1532-4192</identifier><identifier>DOI: 10.1080/07357907.2018.1430816</identifier><identifier>PMID: 29393702</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Antibodies ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - pharmacology ; Antigens, Surface - immunology ; Antigens, Surface - metabolism ; Glutamate Carboxypeptidase II - immunology ; Glutamate Carboxypeptidase II - metabolism ; Humans ; Isotope Labeling ; Male ; Molecular Imaging - methods ; prostate cancer ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - therapy ; PSMA ; radiolabeling ; Radiopharmaceuticals - metabolism</subject><ispartof>Cancer investigation, 2018-02, Vol.36 (2), p.118-128</ispartof><rights>2018 Taylor & Francis Group, LLC 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-38f7c088b9300552fb7389a03e70d6b9477ad5b4c9264d5a23b09969c3a12d1a3</citedby><cites>FETCH-LOGICAL-c366t-38f7c088b9300552fb7389a03e70d6b9477ad5b4c9264d5a23b09969c3a12d1a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29393702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Psimadas, Dimitrios</creatorcontrib><creatorcontrib>Valotassiou, Varvara</creatorcontrib><creatorcontrib>Alexiou, Sotiria</creatorcontrib><creatorcontrib>Tsougos, Ioannis</creatorcontrib><creatorcontrib>Georgoulias, Panagiotis</creatorcontrib><title>Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA</title><title>Cancer investigation</title><addtitle>Cancer Invest</addtitle><description>Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa).</description><subject>Antibodies</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antigens, Surface - immunology</subject><subject>Antigens, Surface - metabolism</subject><subject>Glutamate Carboxypeptidase II - immunology</subject><subject>Glutamate Carboxypeptidase II - metabolism</subject><subject>Humans</subject><subject>Isotope Labeling</subject><subject>Male</subject><subject>Molecular Imaging - methods</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - therapy</subject><subject>PSMA</subject><subject>radiolabeling</subject><subject>Radiopharmaceuticals - metabolism</subject><issn>0735-7907</issn><issn>1532-4192</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EgvL4BFCWbFLGdhLbOyrES4BAUNbWJHZKkBMXOxXq35OohSWrWcy5czWHkFMKUwoSLkDwXCgQUwZUTmnGQdJih0xozlmaUcV2yWRk0hE6IIcxfsJAMpHvkwOmuOIC2IQ8vKJpvMPSOmuSdlbGBGPy5J2tVg5Dct_ioukWCXbmwodk_mEDLtfJbGG7PiZzDAvbj_uXt6fZMdmr0UV7sp1H5P3men51lz4-395fzR7TihdFn3JZiwqkLBUHyHNWl4JLhcCtAFOUKhMCTV5mlWJFZnJkvASlClVxpMxQ5EfkfHN3GfzXysZet02srHPYWb-KmqrhPakkgwHNN2gVfIzB1noZmhbDWlPQo0f961GPHvXW45A721asytaav9SvuAG43ABNV_vQ4rcPzuge186HOmBXNVHz_zt-AI4qf6Q</recordid><startdate>20180207</startdate><enddate>20180207</enddate><creator>Psimadas, Dimitrios</creator><creator>Valotassiou, Varvara</creator><creator>Alexiou, Sotiria</creator><creator>Tsougos, Ioannis</creator><creator>Georgoulias, Panagiotis</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180207</creationdate><title>Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA</title><author>Psimadas, Dimitrios ; Valotassiou, Varvara ; Alexiou, Sotiria ; Tsougos, Ioannis ; Georgoulias, Panagiotis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-38f7c088b9300552fb7389a03e70d6b9477ad5b4c9264d5a23b09969c3a12d1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antibodies</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antigens, Surface - immunology</topic><topic>Antigens, Surface - metabolism</topic><topic>Glutamate Carboxypeptidase II - immunology</topic><topic>Glutamate Carboxypeptidase II - metabolism</topic><topic>Humans</topic><topic>Isotope Labeling</topic><topic>Male</topic><topic>Molecular Imaging - methods</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - therapy</topic><topic>PSMA</topic><topic>radiolabeling</topic><topic>Radiopharmaceuticals - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Psimadas, Dimitrios</creatorcontrib><creatorcontrib>Valotassiou, Varvara</creatorcontrib><creatorcontrib>Alexiou, Sotiria</creatorcontrib><creatorcontrib>Tsougos, Ioannis</creatorcontrib><creatorcontrib>Georgoulias, Panagiotis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Psimadas, Dimitrios</au><au>Valotassiou, Varvara</au><au>Alexiou, Sotiria</au><au>Tsougos, Ioannis</au><au>Georgoulias, Panagiotis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA</atitle><jtitle>Cancer investigation</jtitle><addtitle>Cancer Invest</addtitle><date>2018-02-07</date><risdate>2018</risdate><volume>36</volume><issue>2</issue><spage>118</spage><epage>128</epage><pages>118-128</pages><issn>0735-7907</issn><eissn>1532-4192</eissn><abstract>Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa).</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>29393702</pmid><doi>10.1080/07357907.2018.1430816</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-7907 |
| ispartof | Cancer investigation, 2018-02, Vol.36 (2), p.118-128 |
| issn | 0735-7907 1532-4192 |
| language | eng |
| recordid | cdi_pubmed_primary_29393702 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Antibodies Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacology Antigens, Surface - immunology Antigens, Surface - metabolism Glutamate Carboxypeptidase II - immunology Glutamate Carboxypeptidase II - metabolism Humans Isotope Labeling Male Molecular Imaging - methods prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - metabolism Prostatic Neoplasms - therapy PSMA radiolabeling Radiopharmaceuticals - metabolism |
| title | Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T19%3A59%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiolabeled%20mAbs%20as%20Molecular%20Imaging%20and/or%20Therapy%20Agents%20Targeting%20PSMA&rft.jtitle=Cancer%20investigation&rft.au=Psimadas,%20Dimitrios&rft.date=2018-02-07&rft.volume=36&rft.issue=2&rft.spage=118&rft.epage=128&rft.pages=118-128&rft.issn=0735-7907&rft.eissn=1532-4192&rft_id=info:doi/10.1080/07357907.2018.1430816&rft_dat=%3Cproquest_pubme%3E1993989820%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c366t-38f7c088b9300552fb7389a03e70d6b9477ad5b4c9264d5a23b09969c3a12d1a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1993989820&rft_id=info:pmid/29393702&rfr_iscdi=true |